Rekvina Laboratories FY26 Results: Net loss widens 86% to ₹25.47 lakh
- Net loss widened to ₹25.47 lakh in FY26 from ₹13.71 lakh in FY25
- Revenue from operations began at ₹126.54 lakh after nil in prior year
- Borrowings rose sharply to ₹147.27 lakh, mostly from related parties
- Board approved AGM notice and new independent director appointments
*this image is generated using AI for illustrative purposes only.
Rekvina Laboratories reported a net loss of ₹25.47 lakh for FY26, widening from a loss of ₹13.71 lakh in the previous fiscal year. The company recorded revenue from operations of ₹126.54 lakh, marking its first operational income after a period of suspension.
The board approved the financial statements and the AGM notice on September 3, 2026. The annual general meeting is scheduled for September 29, 2026.
Financial Performance
Rekvina Laboratories commenced operations in FY26, generating total income of ₹126.54 lakh compared to nil in FY25. However, total expenses surged to ₹152.01 lakh from ₹13.71 lakh, driven primarily by purchases of stock-in-trade (₹118.16 lakh) and employee benefits (₹22.99 lakh).
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Revenue | ₹126.54 lakh | Nil | New Operations |
| Total Expenses | ₹152.01 lakh | ₹13.71 lakh | Significant Rise |
| Net Loss | ₹25.47 lakh | ₹13.71 lakh | Widened |
Balance Sheet Signals
Borrowings increased significantly to ₹147.27 lakh from ₹24.69 lakh, largely comprising unsecured loans from related parties. The company’s equity stood at negative ₹122.82 lakh, reflecting accumulated losses and a prior-period error adjustment of ₹64.13 lakh for historical listing and filing fees.
What the Numbers Show
The divergence between operational commencement and profitability is stark. While the company generated ₹126.54 lakh in sales, it incurred a net loss of ₹25.47 lakh. This indicates that the initial cost structure—particularly employee benefits and procurement costs—exceeded the revenue generated in this first year of active trading.
Corporate Governance
The board noted the resignation of Company Secretary Deepak Khandelwal effective September 2, 2026. It also recommended the reappointment of Mrs. Ilaben Pathak and the appointment of Mr. Prateek Jain and Mr. Jay Chintan Patel as independent directors.
Historical Stock Returns for Rekvina Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.99% | +12.54% | +111.12% | +90.68% | 0.0% | 0.0% |
What specific operational milestones or revenue targets has Rekvina Laboratories set for FY27 to bridge the gap between its current cost structure and profitability?
How will the significant increase in unsecured related-party borrowings impact the company's future financing options and interest burden?
What is the strategic rationale behind appointing three new independent directors, and how might this reshape the board's oversight of the company's turnaround plan?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
